Effect of Neoadjuvant Hormone Therapy on Resection Margin and Survival Prognoses in Locally Advanced Prostate Cancer after Prostatectomy Using Propensity-Score Matching
Table 1
Baseline characteristics before and after propensity score matching.
Characteristic
Before propensity score matching
After propensity score matching
RRP
RRP+NHT
p value
RRP
RRP+NHT
p value
N(%)
N(%)
N(%)
N(%)
No. of patients
97 (55.1)
79 (44.9)
50 (50.0)
50 (50.0)
Age
0.710
0.410
<65
33 (34.0)
29 (36.7)
17 (34.0)
21 (42.0)
≥65
64 (66.0)
50 (63.3)
33 (66.0)
29 (58.0)
PSA
<.001
1.000
<40
84 (86.6)
37 (46.8)
37 (74.0)
37 (74.0)
≥40
13 (13.4)
42 (53.2)
13 (26.0)
13 (26.0)
Biopsy Gleason score sum
0.476
0.401
<7
16 (16.5)
10 (12.7)
9 (18.0)
6 (12.0)
≥7
81 (83.5)
69 (87.3)
41 (82.0)
44 (88.0)
Tumor volume
0.178
1.000
<50%
62 (63.9)
58 (73.4)
31 (62.0)
31 (62.0)
≥50%
35 (36.1)
21 (26.6)
19 (38.0)
19 (38.0)
Clinical T stage
2
1 (1.0)
3 (3.8)
1 (2.0)
1 (2.0)
≥3
96 (99.0)
76 (96.2)
49 (98.0)
49 (98.0)
Clinical N stage
0
90 (92.8)
57 (72.1)
45 (90.0)
34 (68.0)
1
7 (7.2)
22 (27.9)
5 (10.0)
16 (32.0)
Extracapsular extension
60 (61.9)
30 (38.0)
0.002
34 (68.0)
22 (44.0)
0.016
Seminal vesicle invasion
37 (38.1)
33 (41.8)
0.625
21 (42.0)
20 (40.0)
0.839
Lymphovascular invasion or emboli
32 (33.0)
9 (11.4)
0.001
17 (34.0)
6 (12.0)
0.009
Perineural invasion
79 (81.4)
52 (65.8)
0.018
40 (80.0)
37 (74.0)
0.476
Apex involvement
25 (25.8)
11 (13.9)
0.053
13 (26.0)
7 (14.0)
0.134
Lymph node dissection
86 (88.7)
76 (96.2)
0.066
43 (86.0)
49 (98.0)
0.059
Neurovascular bundle saving
47 (48.5)
17 (21.5)
<.001
25 (50.0)
12 (24.0)
0.007
Resection margin
36 (37.1)
16 (20.3)
0.015
19 (38.0)
11 (22.0)
0.081
Death
7 (7.2)
11 (13.9)
0.144
6 (12.0)
7 (14.0)
0.766
The p value was calculated using Pearson’s chi-squared test between NHT and non-NHT groups.
